Physician profile
Ming Li
NPI 1982702056
$3,802.83
in general payments reported to CMS, 2019-2025
26 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $963 · 2021: $998 · 2022: $977 · 2023: $110 · 2024: $172 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $627.85 | 2019-2022 | |
| Novo Nordisk INC | $473.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $399.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.67 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $342.67 | 2019-2022 | |
| Abbvie INC. | $266.43 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $182.21 | 2019-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $154.45 | 2019-2021 | |
| Horizon Therapeutics Plc | $136.74 | 2019-2022 | |
| Janssen Biotech, INC. | $116.67 | 2023-2024 | Darzalex, Imbruvica, Tecvayli |
| Xeris Pharmaceuticals, INC. | $104.04 | 2022 | |
| Dexcom, INC. | $94.94 | 2022 | |
| Corcept Therapeutics | $93.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $86.05 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $68.59 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $56.70 | 2024-2025 | Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.90 | 2022-2025 | Fruzaqla |
| Pfizer INC. | $26.56 | 2025 | |
| Genmab U.S., INC. | $25.33 | 2024 | Epkinly |
| Abbott Laboratories | $22.84 | 2021 | |
| Blueprint Medicines Corporation | $22.14 | 2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $20.19 | 2023 | Opdivo |
| Eusa Pharma (US) LLC | $19.93 | 2022 | |
| Recordati_rare_diseases_inc. | $19.93 | 2022 | |
| Geron Corporation | $17.65 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $16.31 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.